Paolo Pevarello, PhD
Dr Paolo Pevarello is a medicinal chemist of 30 years’ experience. Specializing in CNS and oncology drug discovery and development, he has managed large medicinal chemistry groups within the biopharmaceutical industry. Dr Pevarello has contributed to and initiated a number of successful drug discovery projects for Pharmacia and Upjohn, Pharmacia and Pfizer, Newron and Axxam. Among these discoveries has been Safinamide (NW-1015), which has been registered for the treatment of Parkinson’s in USA and Europe and reached Phase II studies for epilepsy and restless leg syndrome. He has provided the medicinal chemistry leadership for the chemical series that generated Ralfinamide (NW-1029), which has reached Phase II for neuropathic pain and NW-3509, which has also reached Phase II studies for schizophrenia. Oncology successes include CDK2 inhibitors PHA-793887 and PHA-690509 (Phase I) and PHA-848125 (Phase II). Dr Pevarello is the author of 53 patents, over 60 peer-reviewed papers and is a member of the editorial board of Pharmaceutical Patent Analyst.